News

Australian fast-food retailers are experiencing sharp share price declines as consumer spending weakens amid cost-of-living pressures. This signals that discretionary spending—even on budget items—is being squeezed, with Domino's, KFC (Collins Foods), and Retail Food Group all hit by double-digit falls. For ASX investors, this reflects broader consumer weakness and suggests earnings headwinds for the sector; watch Q3/Q4 same-store sales data and management guidance on pricing power to assess whether recovery is possible or if the downtrend continues.

Novocure raised its full-year 2026 sales guidance and delivered Q1 revenue that exceeded expectations, triggering a positive market reaction. This suggests stronger-than-anticipated demand for its Tumor Treating Fields (TTF) cancer treatment technology. While significant for the company and healthcare investors, this is a single-stock earnings beat rather than a broad market mover—Australian investors with healthcare or biotech exposure may see indirect benefit through sector funds or global healthcare holdings.

Mastercard beat Q1 earnings expectations and raised its FY26 guidance, signalling confidence in payment volume growth and transaction momentum. This is typically bullish for the payments sector, though the direct impact on Australian investors depends on their exposure to MA or ASX-listed payments infrastructure plays like Square (ASX: SQ2) or local fintech stocks. Watch Q2 guidance execution and whether this reflects broader consumer spending resilience or just strength in cross-border transactions.

Eli Lilly reported Q1 revenue of $19.8B, beating expectations driven by volume growth despite ongoing pricing headwinds in the pharmaceutical sector. The company's forward guidance also exceeded analyst estimates, suggesting confidence in its pipeline and market demand for its products. For Australian investors, this is relevant context for global healthcare exposure and the strength of large-cap pharma; however, direct ASX impact is limited unless held via international ETFs or as part of US equity portfolios.

Eli Lilly's GLP-1 drug sales (Mounjaro for diabetes, Zepbound for weight loss) nearly doubled and exceeded forecasts, driving the stock higher. This validates the massive market opportunity in GLP-1 medications and Lilly's execution ability—a trend that's reshaping the pharmaceutical and obesity treatment landscape globally. For Australian investors, this matters because Lilly is a major US pharma play often held in diversified portfolios, and the GLP-1 boom could sustain growth for years as these drugs gain regulatory approvals and market penetration in Australia and beyond.

Alphabet delivered a better-than-expected earnings result with standout momentum in its cloud division, supporting management's commitment to increased capital expenditure for AI infrastructure. This matters because Big Tech's willingness to spend heavily on AI while meeting profit expectations signals confidence in monetising these investments—a key question for the sector. Australian investors should watch how this spending cycle plays out; Alphabet's cloud strength could pressure local competitors, while any acceleration in AI commercialisation could justify ongoing valuations in the broader tech sector.

Four of the world's largest tech companies reported earnings simultaneously on Wednesday, with Google, Microsoft, and Amazon delivering strong cloud computing results—the core beneficiary of AI spending. This rare cluster reporting provides concrete evidence that the AI boom is translating into real revenue growth, not just hype, though Meta's miss on Wall Street expectations suggests the opportunity is not evenly distributed across the sector. For Australian investors, strength in US tech mega-caps typically supports the ASX's large-cap tech holdings and broader equity sentiment, though the divergence between cloud leaders and Meta hints that AI's winners and losers are becoming clearer.

Alphabet and Microsoft both beat Q1 earnings expectations with strong AI-driven growth—Google Cloud revenue jumped 63% and Microsoft's AI services are running at a $37 billion annual rate. This validates the investment thesis around AI infrastructure and enterprise adoption, reassuring markets that the AI spending cycle is real and monetizable. For Australian investors, this matters because tech-heavy portfolios and ASX-listed cloud operators (like Xero or data-centre plays) often track US cloud giants' momentum; however, the commentary about OpenAI 'sweating' is speculative flavour and shouldn't overshadow the concrete earnings data showing strong fundamentals in cloud and AI services.

The Big Four US tech giants reported earnings simultaneously on Wednesday, with market focus squarely on whether their massive AI infrastructure spending is translating into revenue growth and improving returns on investment. This is crucial for global equity markets—these four companies dominate US indices and have a significant weight in Australian portfolios through ETFs and direct holdings. Investors are essentially deciding whether the AI capex boom justifies current valuations; any disappointment on AI monetisation could trigger a tech selloff that ripples through ASX tech stocks and the broader market.

Equinix, a major global data centre operator, has missed Q1 earnings expectations, triggering a stock selloff. This matters because Equinix is a barometer for cloud computing and AI infrastructure demand—sectors that have driven much of the tech rally. For Australian investors, Equinix operates ASX-listed infrastructure assets and its underperformance could signal softer enterprise spending on cloud and AI deployments, potentially impacting other tech and infrastructure plays in the region.

The Magnificent 7 tech giants are reporting earnings that confirm their massive capital expenditure commitments to AI infrastructure remain on track despite market uncertainty. This matters because these companies drive significant portions of global equity market gains, and their sustained AI investment signals confidence in AI monetisation even as some question ROI timelines. Australian investors should monitor whether this tech strength continues to support the ASX 200, particularly exposure through ETFs and sector plays, while watching if AI capex cycles eventually translate to earnings growth to justify current valuations.

Qualcomm beat Q2 earnings expectations but issued weaker-than-expected Q3 guidance, signalling caution about near-term demand in the semiconductor sector. This mixed result reflects broader uncertainty in chip markets amid inventory normalisations and slowing handset cycles. For Australian investors with tech exposure, this highlights the volatility in semiconductor stocks and suggests the sector's recovery may be more gradual than previously anticipated—watch Qualcomm's commentary on AI demand and customer inventory levels for clues on sector health.

Seagate and NXP have posted stronger-than-expected earnings, reigniting investor appetite for the semiconductor sector after months of caution. This matters because semiconductor strength typically signals improving demand across data centres, AI infrastructure, and consumer electronics—sectors critical to global growth. Australian investors should watch ASX-listed tech and hardware plays for momentum, though direct semiconductor exposure on the ASX is limited; however, this sentiment shift could support broader tech sentiment and benefit Australian IT service providers and data centre operators.

O-I Glass has cut its earnings guidance due to surging global energy costs, signalling broader inflationary pressures affecting manufacturing-heavy industries. This is a cautionary signal for investors in materials and packaging stocks, as energy represents a substantial portion of production costs for glass manufacturers. Australian investors should watch this as a barometer for domestic manufacturers facing similar cost pressures—expect similar guidance cuts from local industrials if energy inflation persists.

AbbVie reported Q1 revenue above expectations but fell short on profit margins, a common pattern when top-line growth doesn't translate to bottom-line strength—often due to higher costs or unfavourable product mix. The company's decision to raise FY26 guidance signals management confidence despite current quarter headwinds, which is generally positive for the stock. Australian investors exposed to US healthcare via ETFs or direct holdings should monitor whether margin pressures persist, as this could impact dividend sustainability, given AbbVie's reputation as a high-yield play.

Biogen has lowered its full-year earnings guidance, citing an unspecified impact from BD (business development or a specific product/deal). This signals operational headwinds—whether from pipeline setbacks, acquisition challenges, or market conditions—that warrant attention. For Australian investors, this matters as Biogen is a major global pharma player; while not ASX-listed, exposure through ETFs or international portfolios is common. Watch for details on what drove the revision and whether it signals broader biotech sector pressures.

Seagate Technology has posted stronger-than-expected earnings results, triggering a renewed rally in its stock price as the market revalues the company upward. This suggests the data storage and hard drive manufacturer is benefiting from recovering demand, possibly tied to AI infrastructure buildout, cloud expansion, or stabilising PC/enterprise cycles. For Australian investors, tech hardware plays like Seagate can serve as bellwethers for broader semiconductor and IT equipment demand; watch whether this momentum extends to other storage and component suppliers.

TotalEnergies has beaten earnings expectations and announced increased shareholder returns, driven by strong oil prices and operational performance. This reflects broader energy sector strength from elevated crude prices, which remains a tailwind for global integrated energy companies and their dividends. Australian investors should note this supports energy sector valuations on the ASX (like $WPL, $STO), though the benefits depend on sustained oil prices above $70–80/bbl.

Robinhood reported Q1 earnings and revenue that fell short of expectations, with crypto revenue and trading volume both declining nearly 50%—a significant headwind given the company's heavy exposure to digital assets. The 10% share price drop reflects investor concern about weakening demand across both traditional and crypto trading segments, suggesting the retail trading boom may be cooling. Australian investors holding $HOOD or considering exposure should monitor whether this signals broader weakness in fintech adoption or is specific to Robinhood's competitive position; the crypto pullback also underscores sentiment volatility in digital assets ahead of potential Fed policy shifts.

Liontown Resources has announced concrete expansion plans for its Kathleen Valley lithium project, triggering early gains in the stock. This is material for Australian lithium investors as Liontown is a significant domestic producer in a sector critical to the energy transition and EV supply chains. The market will be watching for capex requirements, timeline to production, and how this expansion affects returns—key factors for a junior miner's valuation.